1 Min Read
April 10 (Reuters) - Kadmon Holdings Inc:
* ARM, PIVOTAL PHASE 2 CLINICAL TRIAL TO SUPPORT POTENTIAL REGISTRATION OF KD025 IN CGVHD Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.